[Prospects for the limitation of the size of acute myocardial infarction].
D000255:Adenosine Triphosphate / Q000097:blood; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000925:Anticoagulants / Q000008:administration & dosage; D001026:Coronary Artery Bypass; D003329:Coronary Vasospasm / Q000503:physiopathology; D003331:Coronary Vessels / Q000503:physiopathology; D003402:Creatine Kinase / Q000097:blood; D005343:Fibrinolytic Agents / Q000008:administration & dosage; D005440:Fluid Therapy; D005466:Fluorocarbons / Q000627:therapeutic use; D006801:Humans; D006821:Hyaluronoglucosaminidase / Q000627:therapeutic use; D007423:Intra-Aortic Balloon Pumping; D007527:Isoenzymes; D007770:L-Lactate Dehydrogenase / Q000097:blood; D009203:Myocardial Infarction / Q000473:pathology / Q000503:physiopathology / Q000628:therapy*; D009566:Nitrates / Q000627:therapeutic use; D010101:Oxygen Consumption / Q000187:drug effects
D000319:Adrenergic beta-Antagonists; D000893:Anti-Inflammatory Agents; D000925:Anticoagulants; D005343:Fibrinolytic Agents; D005466:Fluorocarbons; D007527:Isoenzymes; D009566:Nitrates; D000255:Adenosine Triphosphate; D007770:L-Lactate Dehydrogenase; D003402:Creatine Kinase; D006821:Hyaluronoglucosaminidase
Perspectives pour la limitation de la taille de l'infarctus myocardique aigu.